Skip to main content Accessibility help

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

  • Domenico De Berardis (a1) (a2), Michele Fornaro (a3) (a4), Laura Orsolini (a4) (a5) (a6), Felice Iasevoli (a7), Carmine Tomasetti (a7), Andrea de Bartolomeis (a7), Nicola Serroni (a2), Ida De Lauretis (a2), Gabriella Girinelli (a4), Monica Mazza (a8), Alessandro Valchera (a4) (a6), Alessandro Carano (a9), Federica Vellante (a1) (a2) (a4), Ilaria Matarazzo (a1) (a2), Giampaolo Perna (a10) (a11) (a12), Giovanni Martinotti (a2) and Massimo Di Giannantonio (a2)...



Agomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients.


30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in “real-world,” everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment.


Agomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose.


Agomelatine’s antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.


Corresponding author

*Address for correspondence: Domenico De Berardis, MD, PhD, National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, “G. Mazzini” Hospital, p.zza Italia 1, 64100 Teramo, Italy. (Email:


Hide All
1. Ferrari, AJ, Charlson, FJ, Norman, RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease study 2010. PLoS Med. 2013; 10(11): e100154.
2. Kessler, RC, Berglund, P, Demler, O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 30953105.
3. Miller, AH, Maletic, V, Raison, CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9): 732741.
4. De Berardis, D, Conti, CM, Campanella, D, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008; 21(2): 319324.
5. Dowlati, Y, Herrmann, N, Swardfager, W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67(5): 446457.
6. Raison, CL, Miller, AH. Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Mod Trends Pharmacopsychiatri. 2013; 28: 3348.
7. Leonard, BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007; 32(10): 17491756.
8. Gambi, F, De Berardis, D, Campanella, D, et al. A retrospective evaluation of the inflammatory marker C-reactive protein (CRP), cholesterol and high-density lipoproteins in patients with major depression: preliminary findings. Eur J Inflamm. 2005; 3(3): 127134.
9. Lam, RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol. 2012; 22(Suppl 3): S492S498.
10. Klemettilä, JP, Kampman, O, Seppälä, N, et al. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res. 2014; 218(3): 277283.
11. Devaraj, S, Valleggi, S, Siegel, D, Jialal, I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep. 2010; 12(2): 110118.
12. Biggio, G. Neurobiology and pharmacology of a new antidepressant therapy. Journal of Psychopathology. 2011; 17(3): 335340.
13. De Bodinat, C, Guardiola-Lemaitre, B, Mocaër, E, Renard, P, Muñoz, C, Millan, MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010; 9(8): 628642.
14. Hickie, IB, Rogers, NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011; 378(9791): 621631.
15. Fornaro, M, Bandini, F, Cestari, L, et al. Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug? Neuropsychiatr Dis Treat. 2014; 10: 907914.
16. De Berardis, D, Di Iorio, G, Acciavatti, T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011; 10(1): 119132.
17. Kennedy, SH, Avedisova, A, Belaïdi, C, Picarel-Blanchot, F, de Bodinat, C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016; 26(2): 378389.
18. Komaram, RB, Nukala, S, Palla, J, Nambaru, LR, Kasturi, SM. A comparative study of efficacy and safety of agomelatine and escitalopram in major depressive disorder. J Clin Diagn Res. 2015; 9(6): VC05VC08.
19. Fornaro, M, Prestia, D, Colicchio, S, Perugi, G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010; 8(3): 287304.
20. Plesničar, BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence. 2014; 8: 603612.
21. First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version (SCID-I/P), Patient ed. New York: Biometrics Research; 2002.
22. Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6(4): 278296.
23. Snaith, RP, Hamilton, M, Morley, S, Humayan, A, Hargreaves, D, Trigwell, P. A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995; 167(1): 99103.
24. Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60(Suppl 22): 2934.
25. Lanquillon, S, Krieg, LC, Bening-Abu-Shach, U, Vedder, H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000; 22(4): 370379.
26. Tuglu, C, Kara, SH, Caliyurt, O, Vardar, E, Abay, E. Increased serum tumor necrosis factor-α levels and treatment response in major depressive disorder. Psychopharmacology. 2003; 170(4): 429433.
27. Uher, R, Tansey, KE, Dew, T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014; 171(12): 12781286.
28. Eyre, HA, Stuart, MJ, Baune, BT. A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 54: 265274.
29. Riedel, M, Möller, HJ, Obermeier, M, et al. Response and remission criteria in major depression—a validation of current practice. J Psychiatr Res. 2010; 44(15): 10631068.
30. Tsai, SY, Chung, KH, Huang, SH, Chen, PH, Lee, HC, Kuo, CJ. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disord. 2010; 16(8): 800808.
31. O’Brien, SM, Scott, LV, Dinan, TG. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry. 2006; 188(5): 449452.
32. De Berardis, D, Marini, S, Fornaro, M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013; 14(6): 1245812483.
33. Kizaki, T, Sato, S, Shirato, K, et al. Effect of circadian rhythm on clinical and pathophysiological conditions and inflammation. Crit Rev Immunol. 2015; 35(4): 261275.
34. Wright, KP Jr, Drake, AL, Frey, DJ, et al. Influence of sleep deprivation and circadian misalignment on cortisol, inflammatory markers, and cytokine balance. Brain Behav Immun. 2015; 47: 2434.
35. MacIsaac, SE, Carvalho, AF, Cha, DS, Mansur, RB, McIntyre, RS. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother. 2014; 15(2): 259274.
36. Martino, M, Rocchi, G, Escelsior, A, Fornaro, M. Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr Neuropharmacol. 2012; 10(2): 97123.
37. Hashimoto, K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 2015; 16(4): 77967801.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed